Funds and ETFs Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Real-time Estimate Tradegate 06:10:03 2024-03-05 am EST 5-day change 1st Jan Change
7.908 EUR -2.15% Intraday chart for Grifols, S.A. -32.64% -48.61%

ETFs positioned on Grifols, S.A.

Name Weight AuM 1st Jan change Investor Rating
0.98% 103 M€ -1.74% -
0.21% 2 M€ -.--%
0.21% 1,292 M€ -0.36%
0.16% 19 M€ +5.26% -
0.05% 6 M€ -.--% -
0.03% 6 M€ -.--%
0.02% 10 M€ -3.35% -
0.02% 0 M€ 0.00% -
0.02% 23 M€ -.--% -
0.02% 786 M€ -.--%
0.01% 280 M€ +12.76%
0.01% 1,166 M€ +0.26% -
0.01% 607 M€ +0.05% -
0.01% 206 M€ -.--%
0.01% 21 M€ +1.71% -
0.01% 284 M€ -.--%
0.01% 341 M€ +5.78% -
0.00% 10 M€ +0.16% -
0.00% 101 M€ +2.44% -
0.00% 6 M€ +0.11% -
0.00% 39 M€ +2.18% -
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (77.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (14.9%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (5.4%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.3%), European Union (11.7%), the United States and Canada (63.6%) and other (19.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
8.082 EUR
Average target price
19.11 EUR
Spread / Average Target
+136.45%
Consensus
  1. Stock
  2. Equities
  3. Stock Grifols, S.A. - BME
  4. Funds and ETFs Grifols, S.A.
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW